Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib

MET exon 14 (METex14) alterations are now an established therapeutically tractable target in non-small cell lung cancer (NSCLC). Recently reported trials of several MET tyrosine kinase inhibitors (TKI) in this patient population have demonstrated promising efficacy data in both the treatment naïve a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Aaron C, Loh, Tracy J, Kwang, Xue Lin, Tan, Gek San, Lim, Kiat Hon, Tan, Daniel S W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987308/
https://www.ncbi.nlm.nih.gov/pubmed/33776501
http://dx.doi.org/10.2147/LCTT.S263610
_version_ 1783668591998009344
author Tan, Aaron C
Loh, Tracy J
Kwang, Xue Lin
Tan, Gek San
Lim, Kiat Hon
Tan, Daniel S W
author_facet Tan, Aaron C
Loh, Tracy J
Kwang, Xue Lin
Tan, Gek San
Lim, Kiat Hon
Tan, Daniel S W
author_sort Tan, Aaron C
collection PubMed
description MET exon 14 (METex14) alterations are now an established therapeutically tractable target in non-small cell lung cancer (NSCLC). Recently reported trials of several MET tyrosine kinase inhibitors (TKI) in this patient population have demonstrated promising efficacy data in both the treatment naïve and pre-treated settings and have led to regulatory approvals. This review will focus on practical diagnostic considerations for METex14 alterations, the trial evidence for capmatinib in this molecular subset including dosing and toxicity management, and the future therapeutic landscape of METex14 altered NSCLC.
format Online
Article
Text
id pubmed-7987308
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79873082021-03-25 Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib Tan, Aaron C Loh, Tracy J Kwang, Xue Lin Tan, Gek San Lim, Kiat Hon Tan, Daniel S W Lung Cancer (Auckl) Review MET exon 14 (METex14) alterations are now an established therapeutically tractable target in non-small cell lung cancer (NSCLC). Recently reported trials of several MET tyrosine kinase inhibitors (TKI) in this patient population have demonstrated promising efficacy data in both the treatment naïve and pre-treated settings and have led to regulatory approvals. This review will focus on practical diagnostic considerations for METex14 alterations, the trial evidence for capmatinib in this molecular subset including dosing and toxicity management, and the future therapeutic landscape of METex14 altered NSCLC. Dove 2021-03-18 /pmc/articles/PMC7987308/ /pubmed/33776501 http://dx.doi.org/10.2147/LCTT.S263610 Text en © 2021 Tan et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Tan, Aaron C
Loh, Tracy J
Kwang, Xue Lin
Tan, Gek San
Lim, Kiat Hon
Tan, Daniel S W
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
title Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
title_full Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
title_fullStr Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
title_full_unstemmed Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
title_short Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
title_sort novel therapies for metastatic non-small cell lung cancer with met exon 14 alterations: a spotlight on capmatinib
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987308/
https://www.ncbi.nlm.nih.gov/pubmed/33776501
http://dx.doi.org/10.2147/LCTT.S263610
work_keys_str_mv AT tanaaronc noveltherapiesformetastaticnonsmallcelllungcancerwithmetexon14alterationsaspotlightoncapmatinib
AT lohtracyj noveltherapiesformetastaticnonsmallcelllungcancerwithmetexon14alterationsaspotlightoncapmatinib
AT kwangxuelin noveltherapiesformetastaticnonsmallcelllungcancerwithmetexon14alterationsaspotlightoncapmatinib
AT tangeksan noveltherapiesformetastaticnonsmallcelllungcancerwithmetexon14alterationsaspotlightoncapmatinib
AT limkiathon noveltherapiesformetastaticnonsmallcelllungcancerwithmetexon14alterationsaspotlightoncapmatinib
AT tandanielsw noveltherapiesformetastaticnonsmallcelllungcancerwithmetexon14alterationsaspotlightoncapmatinib

Ejemplares similares